Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection. Integrase mutant viruses that are resistant to the INSTIs raltegravir (RAL) and elvitegravir (EVG) remain largely sensitive to bictegravir. Coformulated bictegravir with the NRTI emtricitabine (FTC; F) and the NtRTI tenofovir alafenamide (TAF) into an FDC tablet that is suitable for once-daily use may provide a potent, convenient, tolerable, and practical regimen for the long-term treatment of patients with HBV and HIV co-infection. Therefore, this randomized, double-blind, multicenter, active-controlled study will evaluate the safety and efficacy of a FDC of B/F/TAF versus DTG + F/TDF in HIV and HBV treatment-naïve, HIV-1 and HBV coinfected adult subjects. Our site has contributed 1/3 global enrollment.
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Powered by 